A new platform for testing immunosuppressive drugs in organ transplantation and cellular therapies
Official title: Versatile high-throughput Alinity ci assay platform to support multiple laboratory animal users
Funded at Massachusetts General Hospital · NIH-10853206 · Data updated 2026-11-12
This study is working on a new way to test medications that help prevent the body from rejecting transplanted organs, so that patients needing transplants, like those with diabetes or spinal cord injuries, can receive better and safer treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $252,500 |
| NIH project number | 1S10OD034375-01A1 |
| Project ID | NIH-10853206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients awaiting organ transplants or those considering cellular therapies for conditions such as diabetes or spinal cord injuries.
✕Less likely to help
Patients who are not candidates for organ transplantation or cellular therapies, or those with conditions unrelated to the focus of this research, may not benefit.
What this research studies
This research focuses on improving organ transplantation and cellular therapies by developing a high-throughput assay platform that can efficiently test immunosuppressive drugs. The goal is to enhance transplant tolerance and reduce the risk of alloimmune injury to grafts, which is a significant barrier in current treatments. By utilizing this platform, researchers aim to provide timely and tailored treatments for patients in need of transplants, particularly in cases involving allogeneic cells for conditions like diabetes and spinal cord injury. The study will involve the use of various biological samples to assess drug efficacy and safety.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer transplant procedures, improving outcomes for patients requiring organ transplants or cellular therapies.
How similar studies have gone: Previous research has shown promise in improving transplant outcomes through enhanced immunosuppressive strategies, indicating that this approach could build on established findings.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Pierson, Richard N — Massachusetts General Hospital
- Study coordinator: Pierson, Richard N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.